RecruitingNot ApplicableNCT07364331
Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)
Omega- 3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder With (OMNeADHD) A Double Blind Randomized Controlled Trial of High Dose Omega- 3 Fatty Acids in Children and Adolescents With ADHD With Omega- 3 Deficiency.
Sponsor
China Medical University Hospital
Enrollment
100 participants
Start Date
Sep 4, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.
Eligibility
Min Age: 6 YearsMax Age: 18 Years
Inclusion Criteria3
- DSM-5 diagnosis of ADHD
- Did not have any changes of ADHD treatment (pharmacological/psychological) within 4 weeks of entering the trial.
- SNAP-IV inattention subscale >=12, or hyperactivity subscale >=12, or inattention+ hyperactivity subscales >=24
Exclusion Criteria4
- IQ<80
- Allergic to omega-3
- Physical disorders: thyroid function, cancer
- Psychiatric comorbidity: SUD, psychotic disorders, bipolar disorder, major depressive disorder
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTOmega-3
EPA or DHA
DIETARY_SUPPLEMENTPlacebo
olive oil
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07364331
Related Trials
Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children
NCT071937191 location
Spanish-language Executive Function Intervention for Children With Autism and/or ADHD
NCT070843241 location
Central Executive Training and Parent Training for ADHD
NCT054924221 location
Cerebral Palsy and the Study of Brain Activity During Motor Tasks
NCT018297241 location
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283178 locations